ZVRA
Zevra Therapeutics Inc.
NASDAQ: ZVRA · HEALTHCARE · BIOTECHNOLOGY
$10.17
+5.17% today
Updated 2026-04-30
Market cap
$585.24M
P/E ratio
7.33
P/S ratio
5.50x
EPS (TTM)
$1.35
Dividend yield
—
52W range
$7 – $13
Volume
1.1M
WallStSmart proprietary scores
62
out of 100
Grade: C+
Hold
Investment rating
8.0
Growth
A5.0
Quality
C+8.0
Profitability
A7.3
Valuation
B+—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$22.78
+123.99%
12-Month target
$9.15
-10.03%
Intrinsic (DCF)
$22.71
Margin of safety
+62.66%
2 Strong Buy7 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Profit margin 78.20% — above average
+ ROE 85.70% — strong efficiency
+ Free cash flow $5.49M — positive
+ Revenue growth 183.40% QoQ
+ 62.66% below intrinsic value
Risks
No major risks identified
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $10.16M | $27.46M | $23.61M | $106.47M | $106.47M |
| Net income | $-26.77M | $-46.05M | $-105.51M | $83.23M | $12.16M |
| EPS | — | — | — | — | $1.35 |
| Free cash flow | $-18.81M | $-33.83M | $-69.67M | $-2.43M | $5.49M |
| Profit margin | -263.48% | -167.69% | -446.85% | 78.17% | 78.20% |
Peer comparison
Smart narrative
Zevra Therapeutics Inc. trades at $10.17. representing a P/E of 7.33x trailing earnings. Our Smart Value Score of 62/100 indicates the stock is good. TTM revenue stands at $106.47M. with profit margins at 78.20%. Our DCF model estimates intrinsic value at $22.71.
Frequently asked questions
What is Zevra Therapeutics Inc.'s stock price?
Zevra Therapeutics Inc. (ZVRA) trades at $10.17.
Is Zevra Therapeutics Inc. overvalued?
Smart Value Score 62/100 (Grade C+, Hold). DCF value $22.71.
What is the price target of Zevra Therapeutics Inc. (ZVRA)?
The analyst target price is $22.78, representing +124.0% upside from the current price of $10.17.
What is the intrinsic value of Zevra Therapeutics Inc. (ZVRA)?
Based on our DCF model, intrinsic value is $22.71, a +62.7% margin of safety versus $10.17.
What is Zevra Therapeutics Inc.'s revenue?
TTM revenue is $106.47M.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio5.50x
ROE85.70%
Beta0.89
50D MA$9.54
200D MA$9.50
Shares out0.06B
Float0.05B
Short ratio—
Avg volume1.1M
Performance
1 week-4.07%
1 month+2.76%
3 months+7.44%
YTD+7.92%
1 year—
3 years—
5 years—